Toripalimab can induce myositis, myocarditis, and thyroiditis in patients with non-small cell lung cancer
Toripalimab Treatment Linked to Heart and Muscle Inflammation
This case report and literature review describes a 74-year-old male with stage IIIA lung squamous cell carcinoma who developed multiple immu…
A single case study shows a patient with lung cancer developed heart and muscle inflammation after receiving toripalimab treatment.
High-throughput omics approaches identify biomarkers for myocarditis, pneumonitis, and colitis in ICI patients
Mapping biomarkers to track side effects from cancer treatments
This scoping review of 86 studies maps omics-based biomarkers for immune-related adverse events (irAEs) including myocarditis, pneumonitis, …
New research maps complex biological data to help identify and monitor serious side effects caused by immune checkpoint inhibitors.
Abatacept and ruxolitinib show promise for managing steroid-refractory cardiovascular immune-related adverse events
Newer treatments show promise for heart issues from cancer therapies
This narrative review examines cardiovascular immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs…
Newer drugs may help manage serious heart complications, like inflammation and failure, in patients receiving advanced cancer treatments.
Immune checkpoint inhibitors increase risk of myocarditis and other cardiac toxicities in patients
Immune checkpoint inhibitors linked to increased risk of heart issues
This systematic review and network meta-analysis of 135 RCTs indicates that both PD-1/PD-L1 monotherapies and combination therapies increase…
Certain cancer treatments called immune checkpoint inhibitors are linked to a higher risk of heart inflammation and other serious cardiac pr…
High-dose corticosteroids combined with IVIG or plasma exchange are preferred for triple-M syndrome
Triple-M Syndrome Linked to Immune Checkpoint Inhibitor Therapy
This systematic review of case reports and series examines the management of triple-M syndrome following immune checkpoint inhibitor therapy…
Patients receiving immune checkpoint inhibitors may develop triple-M syndrome, a serious combination of muscle, heart, and nerve issues requ…
Gene, inflammation, and metabolic dysregulation drive pathophysiology in pediatric dilated cardiomyopathy
Gene, Inflammation, Metabolism Link in Child Heart Failure
This systematic review examines the role of the gene-inflammation-metabolism axis in pediatric dilated cardiomyopathy. The authors identify …
A new review links genes, inflammation, and metabolism in pediatric dilated cardiomyopathy, offering a roadmap for targeted treatments.
Elevated troponin levels are associated with increased risk of MACE and all-cause mortality in ICI-associated myocarditis
Troponin levels help identify heart inflammation in cancer patients
This meta-analysis evaluates the performance of cardiac troponin as a biomarker for identifying immune checkpoint inhibitor (ICI)-associated…
A new look at cardiac troponin shows it can help doctors spot and predict serious heart risks for patients on certain cancer treatments.
Songjiao Dihuang Tang for Immune Checkpoint Inhibitor-Associated Myocarditis: Trial Protocol
Chinese herbal formula tested for immunotherapy heart side effect
This protocol describes a multicenter, double-blind RCT of Songjiao Dihuang Tang plus standard care vs placebo in 200 patients with mild ICI…
A new trial will test if a traditional Chinese herbal formula can protect cancer patients from a rare but serious heart complication caused …
Meta-analysis reveals CMR and biomarkers key in ICI myocarditis
Heart MRI and Blood Tests Help Detect Immunotherapy Heart Inflammation
In a meta-analysis of 3568 patients, abnormal CMR and elevated cardiac biomarkers were strongly associated with immune checkpoint inhibitor-…
A large review found that heart MRI and blood tests can help diagnose heart inflammation from immunotherapy, but no single test is enough on…
Review proposes pragmatic framework for pediatric heart failure management addressing myocarditis and MIS-C
Why Heart Failure in Kids Needs a Whole New Approach
This review addresses pediatric heart failure, myocarditis, and multisystem inflammatory syndrome in children.
Treating heart failure in children may require a completely different playbook than for adults.
Serum biomarkers stratify disease severity in acute myocarditis cohorts
New Blood Test Predicts Heart Attack Risk in Inflammation
This prospective cohort study analyzed 103 patients across two independent settings to evaluate serum analyses and multimodal data integrati…
A new blood test predicts heart attack risk by spotting inflammation signals from repair workers in the heart muscle.
Systematic review identifies shared immune mechanisms and therapeutic targets across cardiovascular inflammatory diseases
Could one immune problem be driving three different heart conditions?
A systematic review examined shared immunological mechanisms across atherosclerosis, myocarditis, and vasculitis.
Three different heart diseases might share one immune trigger, suggesting new ways to treat plaque buildup, heart muscle inflammation, and b…
Questions about Myocarditis
Can tofacitinib be used to treat steroid-refractory immune checkpoint inhibitor-associated myocarditis?
Tofacitinib has shown promise in treating steroid-refractory immune checkpoint inhibitor-associated myocarditis in specific case reports, particularly when the condition involves other inflammatory issues like myositis.
Full answer →How is pediatric heart failure managed when it involves myocarditis and MIS-C?
Pediatric heart failure from myocarditis or MIS-C is managed by identifying immune triggers, using multimodal tests to distinguish active inflammation from chronic damage, and applying immunomodulatory drugs only when the immune system is the likely cause.
Full answer →Do the benefits of mRNA COVID-19 vaccines outweigh the risk of myocarditis?
Yes, the benefits of mRNA COVID-19 vaccines in preventing severe disease far outweigh the rare, usually mild risk of myocarditis, especially in young males.
Full answer →All Myocarditis Articles
- Toripalimab can induce myositis, myocarditis, and thyroiditis in patients with non-small cell lung cancer
- High-throughput omics approaches identify biomarkers for myocarditis, pneumonitis, and colitis in ICI patients
- Abatacept and ruxolitinib show promise for managing steroid-refractory cardiovascular immune-related adverse events
- Immune checkpoint inhibitors increase risk of myocarditis and other cardiac toxicities in patients
- High-dose corticosteroids combined with IVIG or plasma exchange are preferred for triple-M syndrome
- Gene, inflammation, and metabolic dysregulation drive pathophysiology in pediatric dilated cardiomyopathy
- Elevated troponin levels are associated with increased risk of MACE and all-cause mortality in ICI-associated myocarditis
- Songjiao Dihuang Tang for Immune Checkpoint Inhibitor-Associated Myocarditis: Trial Protocol
- Meta-analysis reveals CMR and biomarkers key in ICI myocarditis
- Review proposes pragmatic framework for pediatric heart failure management addressing myocarditis and MIS-C
- Serum biomarkers stratify disease severity in acute myocarditis cohorts
- Systematic review identifies shared immune mechanisms and therapeutic targets across cardiovascular inflammatory diseases
- ACIP concludes benefits of mRNA COVID-19 vaccination outweigh myocarditis risks
- Tofacitinib used in single case of steroid-refractory multi-organ immune-related adverse events
- MAPSE Predicts Adverse Events in Acute Myocarditis; Lateral MAPSE Shows Superior Performance